Exforge HCT is a combination of three different medications that are used to treat high blood pressure. It contains two different types of drugs, which are an angiotensin II receptor blocker (ARB) and a diuretic. The combination of these two medications helps to lower blood pressure more effectively than either medication alone. Exforge HCT has been approved by the U.S. Food and Drug Administration (FDA) and is available in both generic and brand-name forms. This article will provide a comprehensive guide to the benefits of Exforge HCT and how it can help to manage high blood pressure.
Exforge HCT is a combination of two different medications, amlodipine and valsartan. Amlodipine is a type of calcium channel blocker, which helps to relax blood vessels and reduce the amount of pressure that is put on them. Valsartan is an angiotensin II receptor blocker (ARB), which works to block the action of a hormone called angiotensin II. This hormone can cause the blood vessels to narrow, which can raise blood pressure. The third medication in Exforge HCT is hydrochlorothiazide, which is a diuretic. Diuretics help to reduce the amount of fluid in the body, which can reduce the amount of pressure on the blood vessels.
Exforge HCT works by combining the effects of the three medications. The amlodipine helps to relax the blood vessels, reducing the amount of pressure on them. The valsartan blocks the action of angiotensin II, which helps to keep the blood vessels from narrowing. The hydrochlorothiazide helps to reduce the amount of fluid in the body, which reduces the pressure on the blood vessels. All three medications work together to help lower blood pressure.
Exforge HCT can provide a number of benefits for those with high blood pressure. These benefits include:
Exforge HCT can cause a number of side effects, including:
Exforge HCT is not recommended for those with certain medical conditions, including:
1.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
2.
Do Anatomy Atlases Reflect Social Inequalities?
3.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
4.
Some triple negative breast cancers might be avoided by longer breastfeeding
5.
Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances
3.
Ferroptosis-Modulating Nanocarriers for Solid Tumor Therapy
4.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
5.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Excellence in Hematology
2.
Navigating the Complexities of Ph Negative ALL - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Understanding the causes of anemia in adults beyond nutritional deficiencies
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation